Patent Applications published on Feb 8, 2024

Browse through 8,672 U.S. Patent Applications published on the 06th week of 2024.

Featured patent applications from Feb 8, 2024

Published: 2024-02-08
US20240043506A1
Chemistry; metallurgy
Application 20240043506, fig. 01

SARS-COV-2 ANTIBODIES

The present disclosure is directed to isolated or recombinant antigen binding proteins, such as antibodies, which bind to coronavirus spike (S) protein receptor binding domain (RBD), including S protein RBD from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The present disclosure is also directed to the use of the isolated or recombinant proteins as therapeutic, prophylactic and/or diagnostic agents for respiratory conditions associated with coronavirus infection, such as infection by SARS-CoV-2. The present disclosure is also related to nucleic acid sequences which encode said antigen binding proteins and their expression in recombinant host cells.

Published: 2024-02-08 Assignee: SK BIOSCIENCE CO., LTD..
US20240042008A1
Human necessities
Application 20240042008, fig. 01

VACCINE COMPOSITION FOR PREVENTION OR TREATMENT OF SARS-CORONAVIRUS-2 INFECTION

The present invention provides a recombinant antigen protein for preventing SARS-coronavirus-2 infection, comprising a polypeptide derived from an S1 subunit of a spike protein of SARS-coronavirus-2 and a polypeptide constituting a tetanus toxin (TT) epitope P2 domain, and a vaccine composition comprising the same.

Published: 2024-02-08
US20240043505A1
Chemistry; metallurgy
Application 20240043505, fig. 01

CORONAVIRUS NANOBODIES AND METHODS FOR THEIR USE AND IDENTIFICATION

Disclosed herein are coronavirus neutralizing antibodies and uses thereof for treating and preventing a coronavirus infection in a subject.

Published: 2024-02-08
US20240043507A1
Chemistry; metallurgy
Application 20240043507, fig. 01

ANTIBODIES

The present invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2, and methods and uses thereof in the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19.

Published: 2024-02-08
US20240043508A1
Chemistry; metallurgy
Application 20240043508, fig. 01

ANTIBODY BINDING SPECIFICALLY TO SARS-COV-2 S PROTEIN OR ANTIGEN-BINDING FRAGMENT THEREOF, BISPECIFIC ANTIBODY, AND USES THEREOF

The present invention relates to an anti-SARS-CoV-2 S protein-specific antibody or an antigen-binding fragment thereof, and therapeutic and diagnostic uses thereof. The anti-SARS-CoV-2 S protein-specific antibody or antigen-binding fragment thereof according to the present invention can bind specifically to the S protein, which plays an important role in the infiltration of SARS-CoV-2 into host cells, to inhibit the infection of SARS-CoV-2, and thus can be advantageously used as a therapeutic agent for COVID-19 and as a diagnostic agent and diagnostic kit for COVID-19.

Published: 2024-02-08 Assignee: PURDUE RESEARCH FOUNDATION.
US20240043417A1
Chemistry; metallurgy
Application 20240043417, fig. 02

COMPOUNDS FOR THE TREATMENT OF SARS

Bis-amide inhibitors of SARS-CoV-2 (COVID) and methods of using them to treat a severe acute respiratory syndrome.

Published: 2024-02-08
US20240042011A1
Human necessities
Application 20240042011, fig. 01

CORONAVIRUS VACCINE

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Published: 2024-02-08
US20240045503A1
Physics
Application 20240045503, fig. 01

WEARABLE COMPUTING DEVICE WITH ELECTROPHYSIOLOGICAL SENSORS

A wearable computing device with bio-signal sensors and a feedback module provides an interactive mediated reality (“VR”) environment for a user. The bio-signal sensors receive bio-signal data (for example, brainwaves) from the user and include bio-signal sensors embedded in a display isolator, having a deformable surface, and having an electrode extendable to contact the user's skin. The wearable computing device further includes a processor to: present content in the VR environment via the feedback module; receive bio-signal data of the user from the bio-signal sensor; process the bio-signal data to determine user states of the user, including brain states, using a user profile; modify a parameter of the content in the VR environment in response to the user states of the user. The user receives feedback indicating the modification of the content via the feedback module.

Published: 2024-02-08
US20240046114A1
Physics
Application 20240046114, fig. 01

On-Chip Nanoscale Storage System Using Chimeric DNA

The present disclosure provides systems and methods that can provide portable, real-time accessible DNA memories. An example DNA-based data storage system includes a loading region configured to receive a plurality of DNA-based data storage elements in a suspension fluid and a plurality of microtubes disposed in a capture/release region. The microtubes are configured to capture and release the DNA-based data storage elements. The DNA-based data storage system also includes a linearization region configured to linearize the DNA-based data storage elements and a readout region with a readout device configured to provide information indicative of the respective DNA-based data storage elements.

Published: 2024-02-08
US20240041990A1
Human necessities
Application 20240041990, fig. 01

APPLICATION OF CRISPR/CAS13 FOR THERAPY OF RNA VIRUS AND/OR BACTERIUM INDUCED DISEASES

The present invention relates to composition comprising a clustered, regularly interspaced, short palindromic repeats (CRISPR) system comprising i) at least one CRISPR-associated protein 13 (Cas13) or a nucleotide sequence encoding said Cas13 protein fused with at least one nuclear localization signal (NLS) fused to at least one nuclear export sequence (NES) and ii) at least one guide RNA (gRNA) or a nucleotide sequence encoding said gRNA capable of hybridizing with one or more target RNA molecules. Further, the invention relates to a composition comprising a clustered, regularly interspaced, short palindromic repeats (CRISPR) system comprising i) at least one CRISPR-associated protein 13 (Cas13) or a nucleotide sequence encoding said Cas13 protein fused with at least one nuclear localization signal (NLS) or with at least one nuclear export sequence (NES) and ii) at least one guide RNA (gRNA) or a nucleotide sequence encoding said gRNA capable of hybridizing with one or more target RNA molecules, which is fused to at least one viral export element. The present invention also relates to said compositions for use in therapy. In particular, the present invention relates to said compositions for use in a method of preventing or treating a viral or a bacterial disease in a subject. The present invention further relates to nucleic acid molecules comprising a nucleotide sequence encoding said Cas13 protein and/or said gRNA of said compositions, vectors comprising said nucleic acid molecules and host cells comprising the vectors or the nucleic acid molecules. Further, the present invention relates to kits comprising the compositions. The invention also comprises methods of producing said compositions of the present invention.